127 related articles for article (PubMed ID: 38910780)
21. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.
Hemmelgarn BR; Moist LM; Lok CE; Tonelli M; Manns BJ; Holden RM; LeBlanc M; Faris P; Barre P; Zhang J; Scott-Douglas N;
N Engl J Med; 2011 Jan; 364(4):303-12. PubMed ID: 21268722
[TBL] [Abstract][Full Text] [Related]
22. Hemodialysis catheter design and catheter performance: a randomized controlled trial.
Van Der Meersch H; De Bacquer D; Vandecasteele SJ; Van den Bergh B; Vermeiren P; De Letter J; De Vriese AS
Am J Kidney Dis; 2014 Dec; 64(6):902-8. PubMed ID: 24713222
[TBL] [Abstract][Full Text] [Related]
23. Prevention of catheter lumen occlusion with rT-PA versus heparin (Pre-CLOT): study protocol of a randomized trial [ISRCTN35253449].
Hemmelgarn BR; Moist L; Pilkey RM; Lok C; Dorval M; Tam PY; Berall MJ; LeBlanc M; Toffelmire EB; Manns BJ; Scott-Douglas N;
BMC Nephrol; 2006 Apr; 7():8. PubMed ID: 16608513
[TBL] [Abstract][Full Text] [Related]
24. Catheter lock heparin concentration: effects on tissue plasminogen activator use in tunneled cuffed catheters.
Holley JL; Bailey S
Hemodial Int; 2007 Jan; 11(1):96-8. PubMed ID: 17257362
[TBL] [Abstract][Full Text] [Related]
25. Citrate versus heparin lock for prevention of hemodialysis catheter-related complications: updated systematic review and meta-analysis of randomized controlled trials.
Mai H; Zhao Y; Salerno S; Li Y; Feng Y; Ma L; Fu P
Int Urol Nephrol; 2019 Jun; 51(6):1019-1033. PubMed ID: 31012037
[TBL] [Abstract][Full Text] [Related]
26. Reevaluation of lock solutions for Central venous catheters in hemodialysis: a narrative review.
Wang Y; Sun X
Ren Fail; 2022 Dec; 44(1):1501-1518. PubMed ID: 36047812
[TBL] [Abstract][Full Text] [Related]
27. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction.
Little MA; Walshe JJ
Am J Kidney Dis; 2002 Jan; 39(1):86-91. PubMed ID: 11774106
[TBL] [Abstract][Full Text] [Related]
28. A randomized controlled clinical trial of 4% sodium citrate versus heparin as locking solution for temporary dialysis catheters among hemodialysis patients
.
Abdel Azim ABE; ElSaid TW; El Said HW; Hemida W; Zaghlool S; Ramadan A; Gouda Z; El Masry S; Reda W; Ali HM
Clin Nephrol; 2018 Nov; 90(5):341-349. PubMed ID: 30148449
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness of 30 % trisodium citrate and heparin lock solution in preventing infection and dysfunction of hemodialysis catheters: a randomized controlled trial (CITRIM trial).
Correa Barcellos F; Pereira Nunes B; Jorge Valle L; Lopes T; Orlando B; Scherer C; Nunes M; Araújo Duarte G; Böhlke M
Infection; 2017 Apr; 45(2):139-145. PubMed ID: 27573387
[TBL] [Abstract][Full Text] [Related]
30. Cathasept Line Lock and Microbial Colonization of Tunneled Hemodialysis Catheters: A Multicenter Randomized Controlled Trial.
Kanaa M; Wright MJ; Akbani H; Laboi P; Bhandari S; Sandoe JA
Am J Kidney Dis; 2015 Dec; 66(6):1015-23. PubMed ID: 26141306
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of urokinase lock to treat thrombotic dysfunction of tunneled hemodialysis catheters: A retrospective cohort study.
Van Hulle F; Bonkain F; De Clerck D; Aerden D; Vanwijn I; Tielemans C; Wissing KM
J Vasc Access; 2019 Jan; 20(1):60-69. PubMed ID: 29893163
[TBL] [Abstract][Full Text] [Related]
32. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis.
Eyrich H; Walton T; Macon EJ; Howe A
Am J Health Syst Pharm; 2002 Aug; 59(15):1437-40. PubMed ID: 12166043
[TBL] [Abstract][Full Text] [Related]
33. Tissue plasminogen activator as a hemodialysis catheter locking solution.
McGill RL; Spero JA; Sysak JC; Sandroni SE; Marcus RJ
Hemodial Int; 2008 Jul; 12(3):348-51. PubMed ID: 18638092
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of citrate 4% and heparin as tunneled-catheters-locking solution in chronic hemodialysis].
Chazot G; Mehdi M; Lorriaux C; Deleaval P; Mayor B; Jean G; Chazot C; Lechevallier S; Moncel O; Vo-Van C; Hurot JM
Nephrol Ther; 2018 Feb; 14(1):42-46. PubMed ID: 29191576
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients.
Moore CL; Besarab A; Ajluni M; Soi V; Peterson EL; Johnson LE; Zervos MJ; Adams E; Yee J
Clin J Am Soc Nephrol; 2014 Jul; 9(7):1232-9. PubMed ID: 24970874
[TBL] [Abstract][Full Text] [Related]
36. The impact of catheter-restricted filling with cefotaxime and heparin on the lifespan of temporary hemodialysis catheters: a case controlled study.
Saxena AK; Panhotra BR
J Nephrol; 2005; 18(6):755-63. PubMed ID: 16358235
[TBL] [Abstract][Full Text] [Related]
37. Low dose heparin lock (1000 U/mL) maintains tunnelled hemodialysis catheter patency when compared with high dose heparin (5000 U/mL): A randomised controlled trial.
Chu G; Fogarty GM; Avis LF; Bergin S; McElduff P; Gillies AH; Choi P
Hemodial Int; 2016 Jul; 20(3):385-91. PubMed ID: 26833752
[TBL] [Abstract][Full Text] [Related]
38. The effect of heparinized catheter lock solutions on systemic anticoagulation in hemodialysis patients.
Thomson PC; Morris ST; Mactier RA
Clin Nephrol; 2011 Mar; 75(3):212-7. PubMed ID: 21329631
[TBL] [Abstract][Full Text] [Related]
39. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial.
Maki DG; Ash SR; Winger RK; Lavin P;
Crit Care Med; 2011 Apr; 39(4):613-20. PubMed ID: 21200319
[TBL] [Abstract][Full Text] [Related]
40. Low Concentration Trisodium Citrate as a Non-inferior Locking Agent for Non-tunneled Dialysis Catheters in the Asian Setting.
Jayaprakash V; Jagadeswaran D; Ezhilmathi K; Sathiapriya A; Vamsikrishna M; Indhumathi E; Jayakumar M
Indian J Nephrol; 2019; 29(6):410-414. PubMed ID: 31798223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
